KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash from Financing Activities (2016 - 2025)

Amgen has reported Cash from Financing Activities over the past 17 years, most recently at -$1.2 billion for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$1.2 billion for Q4 2025, up 12.86% from a year ago — trailing twelve months through Dec 2025 was -$10.9 billion (down 15.34% YoY), and the annual figure for FY2025 was -$10.9 billion, down 15.34%.
  • Cash from Financing Activities for Q4 2025 was -$1.2 billion at Amgen, up from -$2.9 billion in the prior quarter.
  • Over the last five years, Cash from Financing Activities for AMGN hit a ceiling of $21.5 billion in Q1 2023 and a floor of -$6.6 billion in Q4 2021.
  • Median Cash from Financing Activities over the past 5 years was -$1.8 billion (2021), compared with a mean of -$576.7 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 663.39% in 2021 and later soared 712.09% in 2023.
  • Amgen's Cash from Financing Activities stood at -$6.6 billion in 2021, then surged by 84.0% to -$1.0 billion in 2022, then surged by 362.54% to $2.8 billion in 2023, then plummeted by 151.09% to -$1.4 billion in 2024, then increased by 12.86% to -$1.2 billion in 2025.
  • The last three reported values for Cash from Financing Activities were -$1.2 billion (Q4 2025), -$2.9 billion (Q3 2025), and -$2.7 billion (Q2 2025) per Business Quant data.